OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) was established in 2010 to assess oncology drugs and bring consistency to the assessment across provinces/territories. In April 2014, pCODR was transferred to the Canadian Agency for Drugs and Technologies in Health (CADTH). This research aims to see what effect this transfer has had on the number of appraisals and recommendation rates conducted by pCODR. METHODS: All publically available pCODR reports were extracted up to 30^th November 2016 and the drug, indication, date and outcome were extracted. Statistical comparisons were made using Student’s t-test. RESULTS: CONCLUSIONS: The number of technologies appraised by pCODR and recommendation rates for these have fluctuated from year to year, but no meaningful trends have been observed since the transfer of pCODR to CADTH. However, this transfer began in April 2014, with a second phase aimed at aligning pCODR and CADTH review criteria and best-practice review processes that only commenced in April 2015. Thus, the full effects of this transfer may not yet be clear.